CompletedNot Applicable

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II)

France, Germany, Italy44 participantsStarted 2019-02-14

Plain-language summary

This LIGHTSITE II study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.

Who can participate

Age range50 Years – 120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Choroidal neovascularization (CNV) defined as pathologic angiogenesis originating from the choroidal vasculature that extends through a defect in Bruch's membrane
✕. Serous and/or hemorrhagic detachment of the neurosensory retina or retinal pigment epithelial (RPE)
✕. Retinal hard exudates (a secondary phenomenon resulting from chronic intravascular leakage)
✕. Subretinal and sub-RPE fibrovascular proliferation
✕. Disciform scar (subretinal fibrosis)

What they're measuring

Best Corrected Visual Acuity

Timeframe: Month 9

Trial details

NCT IDNCT03878420

SponsorLumiThera, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-01-22

View on ClinicalTrials.gov More Dry Age-related Macular Degeneration trials